17-Nov-2026 14:02:36
CAPLIN POINT : US FDA CLASSIFIES SUBSIDIARY FACILITY AS OAI
• US FDA determined inspection classification of Caplin Steriles Limited (subsidiary) facility as Official Action Indicated (OAI) • Facility at Gummidipoondi m…
Latest market headlines for CAPLIPOINT on Terminal.
17-Nov-2026 14:02:36
• US FDA determined inspection classification of Caplin Steriles Limited (subsidiary) facility as Official Action Indicated (OAI) • Facility at Gummidipoondi m…
13-Nov-2026 10:04:19
CAPLIN POINT says Mexico Is A High Growth Market For Us | Oncology Segment Will See 37-38% Margin
13-Nov-2026 10:04:02
CAPLIN POINT says Won $17-18 m Worth Of Govt Tenders Over The Past 3-4 Quarters
13-Nov-2026 10:03:47
CAPLIN POINT says Latin America Accounts For 80% Of Our Revenue |Generic Is Our Biggest Segment, Primarily Driven By Pvt Market
12-Nov-2026 18:18:18
CAPLIN POINT LABORATORIES Q2 FY27 CONCALL: MAINTAINS 20–25% FY27 US GROWTH & 25–26% PAT MARGIN GUIDANCE; TARGETS DOUBLING CSU REVENUE & PROFITABILITY, Q3–Q4 US…
12-Nov-2026 13:14:05
• Capex Programme: Allocated over ₹1,000 Cr for manufacturing expansion, with approximately 50% of investments nearing completion. • Investment Timeline: Remai…
12-Nov-2026 13:13:00
• H1 FY27 Performance: Revenue crossed ₹1,300 Cr and EBITDA exceeded ₹500 Cr, both growing approximately 20% YoY. • Central America Orders: Won tenders worth $…
12-Nov-2026 13:08:27
REVENUE UP 17.94% AT ₹629.84 CR (YOY), UP 3.19% (QOQ) EBITDA UP 18.00% AT ₹223.22 CR (YOY), UP 4.56% (QOQ) MARGINS AT 35.44% VS 35.42% (YOY), 34.98% (QOQ)
01-Sept-2026 18:01:08
• Caplin One Labs Limited (COL), subsidiary of the company, received confirmation of compliance with Good Manufacturing Practices (GMP) from INVIMA (Colombia).…
21-Aug-2026 19:14:26
• Unannounced inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility in Gummidipoondi conducted between August 13, 2026, and August 21…